drugset / Trial / NCT03903211
Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The overall goal of this imaging trial is to evaluate crosssectional difference and longitudinal changes of \[18F\]PI-2620, a tau targeted positron emission computed tomography radioligand, in cognitively normal individuals, and subjects with mild cognitive impairment and Alzheimer's disease.
Timeline
- Start
- 2019-04-09
- Primary completion
- 2021-02-28
- Completion
- 2021-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [18F]PI-2620 | Diagnostic / imaging agent | — | Intravenous |